
Benzinga Pro data, Adaptimmune Therapeutics (NASDAQ:ADAP) reported Q1 sales of $3.58 million. Earnings fell to a loss of $50.27 million, resulting in a 29.36% decrease from last quarter. In Q4, Adaptimmune Therapeutics brought in $1.42 million in sales but lost $38.86 million in earnings.